Tag: Biopharma Perspective
-
Eli Lilly to Acquire Merida Biosciences for Up to $2.875 Billion
Eli Lilly will acquire Merida Biosciences for up to $2.875 billion, gaining a precision autoantibody-degradation platform and multiple immunology programs.
-
Priovant Wins FDA Approval for Lisraya in Dermatomyositis
The FDA approved Lisraya (brepocitinib), the first oral treatment option for adults with dermatomyositis, based on positive Phase 3 VALOR results.
-
Takeda Wins FDA Approval for First-in-Class Mimrylo in Polycythemia Vera
The FDA approved Mimrylo (rusfertide), the first hepcidin mimetic for polycythemia vera, introducing iron restriction as a new strategy to control excessive red blood cell production.
-
How Rusfertide Controls Red Blood Cell Overproduction in Polycythemia Vera
Rusfertide mimics hepcidin to reduce ferroportin-mediated iron export, restricting the iron available for excessive red blood cell production in polycythemia vera.
-
Eli Lilly Wins FDA Approval for Mounjaro to Reduce Cardiovascular Risk
The FDA approved Mounjaro (tirzepatide) to reduce major cardiovascular events in adults with type 2 diabetes at high cardiovascular risk.
-
How Tirzepatide May Reduce Cardiovascular Risk
Tirzepatide combines GIP and GLP-1 receptor signaling to improve glucose, weight and other cardiometabolic factors associated with cardiovascular risk.
-
Roche and Eli Lilly Win FDA Clearance for Alzheimer’s Blood Test
Roche and Eli Lilly received FDA clearance for Elecsys pTau217, a single-biomarker blood test designed to assess Alzheimer’s-related amyloid pathology.
-
Revolution Medicines Wins FDA Approval for Rasonque in Metastatic Pancreatic Cancer
The FDA approved Rasonque (daraxonrasib) for metastatic pancreatic adenocarcinoma after Phase 3 RASolute 302 showed a major survival benefit over chemotherapy.
-
Jazz Wins First-Line FDA Approval for Ziihera in HER2-Positive Gastroesophageal Cancer
The FDA approved Ziihera for first-line HER2-positive gastroesophageal adenocarcinoma, strengthening Jazz Pharmaceuticals’ solid-tumor oncology strategy.
-
How Ziihera Targets HER2 Differently From Trastuzumab
Ziihera binds two HER2 extracellular domains simultaneously, promoting receptor internalization and immune-mediated killing through a mechanism distinct from trastuzumab and Enhertu.